A rare case of coronary artery complication in a child with systemic juvenile idiopathic arthritis and macrophage activation syndrome: case report and literature review

Pediatr Rheumatol Online J. 2024 Jan 2;22(1):4. doi: 10.1186/s12969-023-00944-2.

Abstract

A rare case of coronary artery involvement in a child with Systemic Juvenile Idiopathic Arthritis (sJIA) complicated by Macrophage Activation Syndrome (MAS) is reported. The patient initially received an inaccurate diagnosis of Kawasaki Disease, sepsis, and mycoplasma infection and showed no improvement after Intravenous Immune Globulin (IVIG) treatment. Upon admission, symptoms included diffuse red rash, swelling of the limbs, lymph node enlargement, and hepatosplenomegaly. Post investigations, a diagnosis of sJIA and MAS was confirmed, and treatment involved a combination of hormones (methylprednisolone) and immunosuppressive drugs (methotrexate). The revealed widened coronary artery diameter was managed with a disease-specific treatment plan and prophylactic plus low-dose aspirin anti-coagulation therapy. Under this management, MAS was well controlled, and follow-ups showed normalization of the child's coronary artery structure and function. This case and the associated literature review underscore the importance of early recognition, diagnosis, treatment, and long-term monitoring for children presenting with sJIA and MAS complicated by coronary artery involvement.

Keywords: Coronary artery involvement; Macrophage activation syndrome (MAS); Systemic juvenile idiopathic arthritis (sJIA).

Publication types

  • Review
  • Case Reports

MeSH terms

  • Arthritis, Juvenile* / complications
  • Arthritis, Juvenile* / diagnosis
  • Arthritis, Juvenile* / drug therapy
  • Child
  • Coronary Vessels / diagnostic imaging
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Macrophage Activation Syndrome* / diagnosis
  • Macrophage Activation Syndrome* / drug therapy
  • Macrophage Activation Syndrome* / etiology
  • Methotrexate / therapeutic use

Substances

  • Immunosuppressive Agents
  • Methotrexate